Mease, P. J., Gladman, D. D., Strand, V., Vlam, K. d., Covarrubias-Cobos, J. A., Graham, D., . . . Hsu, M. (2019). Tofacitinib or adalimumab versus placebo: Patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. BMJ Publishing Group.
Chicago Style (17th ed.) CitationMease, Philip J., et al. Tofacitinib or Adalimumab Versus Placebo: Patient-reported Outcomes from OPAL Broaden—a Phase III Study of Active Psoriatic Arthritis in Patients with an Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs. BMJ Publishing Group, 2019.
MLA (9th ed.) CitationMease, Philip J., et al. Tofacitinib or Adalimumab Versus Placebo: Patient-reported Outcomes from OPAL Broaden—a Phase III Study of Active Psoriatic Arthritis in Patients with an Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs. BMJ Publishing Group, 2019.